Browse All

Current Filters

CLEAR FILTER x

TITLE

Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years

Author:Wiendl, Heinz   Hauser, Stephen   Nicholas, Jacqueline   De Seze, Jerome   Meuth, Sven   Giacomini, Paul   Robertson, Derrick   Wray, Sibyl   Bhatt, Alit   Hu, Xixi   Fu, Haoyi   Jehl, Valentine   Sullivan, Roseanne   Boer, Ibolya   Cohen, Jeffrey   Kappos, Ludwig   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.010  

Author Institution:University of Münster, Münster, Germany, Muenster, Germany  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, United States, San Francisco, CA  OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, Columbus, OH  University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France  Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, Duesseldorf, Germany  Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, Tampa, FL  Hope Neurology MS Center, Knoxville, TN, USA, Knoxville, TN  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma A.G. Basel, Switzerland, Basel, Switzerland  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Headorgans, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

Safety and Efficacy of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: 1-year Analysis of the ENLIGHTEN Study

Author:Naismith, Robert   Zivadinov, Robert   Morrow, Sarah   Bass, Ann   Obeidat, Ahmed   Riser, Emily   Wray, Sibyl   Cristofanilli, Massimiliano   Riolo, Jon   Thorpe, Andrew   Chaudhry, Burhan   Mohiuddin, Kamran   Cheng, Chun-Yen   DeLuca, John   

Session Name:P10: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 3  

Topic:Multiple Sclerosis  

Program Number:P10.014  

Author Institution:Washington University School of Medicine, St Louis, Missouri, Saint Louis, MO  Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, Buffalo, NY  London Health Sciences Centre, University Hospital, University of Western Ontario, London, Ontario, Canada, and Department of Clinical Neurological Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, London, ON, Canada  Neurology Center of San Antonio, San Antonio, Texas, San Antonio, TX  Department of Neurology, The Medical College of Wisconsin, Milwaukee, Wisconsin, Milwaukee, WI  Alabama Neurology Associates, Birmingham, Alabama, Birmingham, AL  Hope Neurology MS Center, Knoxville, Tennessee, Knoxville, TN  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Bristol Myers Squibb, Princeton, New Jersey, Amherst, NY  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ  

Brain Volume Changes Over 1 Year in Ozanimod-treated Patients with Early-relapsing Multiple Sclerosis: An Interim Analysis of the ENLIGHTEN Study

Author:Zivadinov, Robert   Naismith, Robert   Morrow, Sarah   Bass, Ann   Obeidat, Ahmed   Riser, Emily   Wray, Sibyl   Riolo, Jon   Chaudhry, Burhan   Thorpe, Andrew   Cheng, Chun-Yen   DeLuca, John   

Session Name:P11: Multiple Sclerosis: Epidemiology and Neuroimaging  

Topic:Multiple Sclerosis  

Program Number:P11.017  

Author Institution:Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, Buffalo, NY  Washington University School of Medicine, St Louis, Missouri, Saint Louis, MO  London Health Sciences Centre, University Hospital, University of Western Ontario, London, Ontario, Canada, and Department of Clinical Neurological Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, London, ON, Canada  Neurology Center of San Antonio, San Antonio, Texas, San Antonio, TX  Medical College of Wisconsin, Milwaukee, Wisconsin, Milwaukee, WI  Alabama Neurology Associates, Birmingham, Alabama, Birmingham, AL  Hope Neurology MS Center, Knoxville, Tennessee, Knoxville, TN  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Bristol Myers Squibb, Princeton, New Jersey , Princeton, NJ  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ